DaTscan

DaTscan. It is a diagnostic nuclear medicine imaging technique that utilizes a radiopharmaceutical agent to visualize the density of dopamine transporters in the brain. The procedure is primarily used to assist in the evaluation of adults with suspected parkinsonian syndromes, such as Parkinson's disease, by differentiating them from conditions like essential tremor which do not involve dopaminergic degeneration. By providing an objective assessment of presynaptic striatal dopaminergic function, it serves as a valuable tool in the diagnostic workup of movement disorders.

Medical uses

The primary clinical application is to aid in differentiating Parkinson's disease and other neurodegenerative parkinsonian syndromes, including multiple system atrophy and progressive supranuclear palsy, from essential tremor or drug-induced parkinsonism. It is indicated when a patient's clinical presentation is uncertain, helping neurologists at institutions like the Mayo Clinic or Cleveland Clinic make more confident diagnoses. The scan is not used for routine diagnosis of established Parkinson's disease nor for monitoring disease progression or response to therapies like levodopa. Regulatory approval from agencies like the U.S. Food and Drug Administration and the European Medicines Agency is specific for this diagnostic differentiation.

Procedure

The patient is administered an intravenous injection of the radiopharmaceutical Ioflupane, which is labeled with the gamma-emitting isotope Iodine-123. Following injection, there is a mandatory waiting period of approximately three to six hours to allow for adequate uptake in the brain and clearance from background tissues. Imaging is then performed using a gamma camera system, which rotates around the patient's head to acquire data for single-photon emission computed tomography. The patient must remain still during the scan, and precautions are taken to protect the thyroid gland from free radioiodine, typically with pre-administration of potassium iodide.

Interpretation of results

The resulting SPECT images are analyzed visually and quantitatively to assess the integrity of dopaminergic neurons in the striatum, a region comprising the caudate nucleus and the putamen. A normal scan shows symmetrical, comma-shaped or crescent-shaped uptake in these structures. An abnormal scan, indicative of a parkinsonian syndrome, shows reduced uptake, often starting asymmetrically in the posterior putamen, potentially progressing to an absent or period-shaped pattern. The findings are interpreted by a specialist in nuclear medicine or neuroradiology in the context of the patient's clinical history from a referring neurologist.

Mechanism of action

The radiopharmaceutical Ioflupane acts as a molecular analog that binds with high affinity to the presynaptic dopamine transporter protein, which is located on the terminals of dopaminergic neurons projecting from the substantia nigra to the striatum. The Iodine-123 isotope emits gamma rays that are detected externally. The concentration of the tracer in the striatum is therefore proportional to the density of functional dopamine terminals. This mechanism allows the imaging system to map the distribution of these terminals, providing a functional assessment distinct from anatomical imaging like magnetic resonance imaging.

History and development

The development of Ioflupane and the DaTscan technique followed decades of research into the neurochemistry of Parkinson's disease. Key foundational work was conducted by scientists like Oleh Hornykiewicz, who identified the dopamine deficiency in the striatum. The radiopharmaceutical was developed through collaboration between academia and industry, with GE Healthcare playing a major role in its commercialization. It received marketing approval from the European Medicines Agency in 2000 and later from the U.S. Food and Drug Administration in 2011, following clinical trials that demonstrated its efficacy and safety.

Limitations and risks

The test cannot differentiate between the various types of neurodegenerative parkinsonian syndromes, such as Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. It also has limited utility in very early or pre-symptomatic stages of disease. Risks are primarily associated with radiation exposure from Iodine-123, though the effective dose is comparable to other nuclear medicine procedures like a myocardial perfusion scan. Allergic reactions are rare. The use of medications that affect the dopamine transporter, such as certain amphetamines, bupropion, or cocaine, can interfere with tracer uptake and must be discontinued prior to imaging. Category:Medical tests Category:Nuclear medicine Category:Neurology